36
Views
2
CrossRef citations to date
0
Altmetric
Rapid Communication

Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents

, &
Pages 421-426 | Received 20 May 2009, Accepted 18 Jun 2009, Published online: 08 Feb 2010
 

Abstract

The fungal opportunist Cryptococcus neoformans forms biofilms in vitro and in vivo. C. neoformans has an unusual ability to grow over a wide range of temperatures, and is one of only two species in the genus able to grow at 37°C. The optimum growth temperature in the laboratory is 30°C, but Clinical and Laboratory Standards Institute (CLSI) planktonic susceptibility testing is performed at 35°C. We investigated whether these growth temperatures affected C. neoformans biofilm formation and drug resistance. Biofilms of 30 strains of C. neoformans were grown at 30°C or 35°C, and antifungal susceptibilities evaluated at 30°C or 35°C using minimum biofilm eradication endpoints. At 35°C, biofilms from 40% of the strains were more susceptible to flucytosine, 30% were more susceptible to nystatin, 27% were more susceptible to amphotericin, and 20% were more susceptible to fluconazole, as compared to 30°C. The reverse, that is an increased susceptibility at 30°C, only occurred with a single strain using nystatin or fluconazole. For the remaining strains, biofilm susceptibility was equivalent at the two temperatures. Biofilm colony forming units (CFU)s, as measured indirectly by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction, were greater at 35°C than at 30°C for the majority of the strains. Thus, growth temperature does affect C. neoformans biofilm properties, but factors other than relative biofilm CFUs/ml must be involved in the increased drug susceptibility at 35°C.

Acknowledgements

We thank E. Jacobson (McGuire Veterans Administration Medical Center) for providing strains B3501 and NIH 326. This research was supported by grants R01 CA 90441-01-05, 2R56-CA 09441-06A1 and 5R01 CA 090441-07 from the Division of Cancer Treatment and Diagnosis, NCI, DHHS, the Arizona Disease Control Research Commission, the Robert B. Dalton Endowment Fund and Dr. A. Keith.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This paper was first published online on Early Online on 01 February 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.